ScienceDex / Researcher record
Reich, Jeffrey
- Sparian Biosciences, Inc. (no department on record)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
- Top 5% Funded
- Early Career
NIH Funding · FY2022
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2021 | $4,914,440 | 2 | #721 |
| 2022 | $4,628,029 | 1 | #825 |
| 2023 | $7,392,347 | 2 | #409 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20212 records
- FY2022 · selected1 record
- FY20232 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2021 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2022 award records by amount
NIH award records listing Reich, Jeffrey as a PI. Multi-PI records show the full award amount for context.
- 5UH3DA048379-04UH3Contact PIArylepoxamides: A new class of potent, safer analgesics$4.6Maward amount
Award organization
Organizations that administered FY2022 awards listing Reich, Jeffrey as a PI.
FY2022 award administered by Sparian Biosciences, Inc. (NY).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2021First NIH AwardSparian Biosciences, Inc.
- 2021$500K Cumulative Funding
- 2021$1M Cumulative Funding
- 2021$2M Cumulative Funding
- 2021Entered Top 50% NationallyRanked #721
- 2021Entered Top 25% NationallyRanked #721
- 2021Entered Top 10% NationallyRanked #721
- 2021Entered Top 5% NationallyRanked #721
- 2022$5M Cumulative Funding
- 2023$10M Cumulative Funding